MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in West Conshohocken, Pennsylvania. The company focuses on developing and commercializing therapeutic treatments for cardiovascular, metabolic, and liver diseases. After nearly two decades of clinical development, Madrigal achieved a significant milestone in 2024 with the FDA approval and commercial launch of <b>Rezdiffra</b> (resmetirom), marking the first approved treatment for non-alcoholic steatohepatitis (NASH), a serious liver condition. The company has transitioned from a pure research and development organization to a commercial-stage biopharmaceutical company with established revenue streams and plans for international expansion.